Design and development of synthetic peptide vaccines: past, present and future (Q36899093)

17 August 2017

1 reference

title

Design and development of synthetic peptide vaccines: past, present and future (English)

1 reference

17 August 2017

1 reference

Cornelis J. M. Melief

series ordinal

2

object named as

Cornelis J M Melief

1 reference

PubMed ID

17669012

17 August 2017

Sjoerd H van der Burg

series ordinal

4

object named as

Sjoerd H van der Burg

1 reference

17 August 2017

Martijn S Bijker

1

1 reference

PubMed ID

17669012

17 August 2017

Rienk Offringa

series ordinal

3

1 reference

17 August 2017

1 August 2007

1 reference

Expert Review of Vaccines

17 August 2017

1 reference

17 August 2017

6

1 reference

17 August 2017

4

1 reference

17 August 2017

591-603

1 reference

Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Cellular peptide composition governed by major histocompatibility complex class I molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Peptide-induced antiviral protection by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

T cell priming versus T cell tolerance induced by synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Heteroclitic immunization induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor beta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Helper activity is required for the in vivo generation of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Adjuvant activity of incomplete Freund's adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immune responses to ISCOM formulations in animal and primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Therapeutics targeting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Toll-like receptor 2 controls expansion and function of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

B cells directly tolerize CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of ir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immunogenicity of Bcl-2 in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

21 January 2018

A license to remember.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.591

21 January 2018

Identifiers

DOI

10.1586/14760584.6.4.591

1 reference

17 August 2017

1 reference

PubMed ID

17669012